1598-61-4

Basic information

• Product Name: 2-Fluoropurine
• Synonyms: 2-FLUOROPURINE;1H-Purine, 2-fluoro- (9CI);2-Fluoro-1H-purine;2-fluoro-7H-purine
• CAS NO: 1598-61-4
• Molecular Formula: C₅H₃FN₄
• Molecular Weight: 138.1
• Product Categories: PYRIMIDINE;Purines
• Mol File: 1598-61-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 540.3 °C at 760 mmHg
• Flash Point: 280.6 °C
• Appearance: /
• Density: 1.61 g/cm³
• Vapor Pressure: 3.42E-11mmHg at 25°C
• Refractive Index: 1.69
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Fluoropurine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoropurine(1598-61-4)
• EPA Substance Registry System: 2-Fluoropurine(1598-61-4)

Safety Data

• Hazardous Substances Data: 1598-61-4(Hazardous Substances Data)

Usage

General Description

2-Fluoropurine is a chemical compound with the molecular formula C5H4FN3O. It is a derivative of the purine base, with a fluorine atom substituted at the 2 position. 2-Fluoropurine has been studied for its potential biological activity, including its use as a building block in the synthesis of nucleoside analogs and antiviral drugs. 2-Fluoropurine has also been investigated for its potential as an antimetabolite and for its ability to inhibit the growth of cancer cells. It has been the subject of research for its potential role in the treatment of various diseases due to its impact on cellular processes.

InChI:InChI=1/C5H3FN4/c6-5-7-1-3-4(10-5)9-2-8-3/h1-2H,(H,7,8,9,10)

Upstream product

• 452-06-2 7H-purin-2-amine 
• 452-06-2 9H-purin-2-amine 
• 212650-30-1 N-[(1,3-benzodioxol-5-yl)methyl]piperidine-2-acetamide 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 71-36-3 butan-1-ol 
• 10310-21-1 2-Amino-6-chloropurin 
• 1651-29-2 6-chloro-2-fluoropurine 

Relevant articles and documents

N-Substituted pyrrolopyrimidines and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors

The RSK2 kinase is the downstream effector of the Ras/Raf/MEK/ERK pathway, that is often aberrantly activated in acute myeloid leukemia (AML). Recently, we reported a structure-activity study for BI-D1870, the pan-RSK inhibitor, and identified pteridinones that inhibited cellular RSK2 activity that did not result in concomitant cytotoxicity. In the current study, we developed a series of pyrrolopyrimidines and purines to replace the pteridinone ring of BI-D1870, with a range of N-substituents that extend to the substrate binding site to probe complementary interactions, while retaining the 2,6-difluorophenol-4-amino group to maintain interactions with the hinge domain and the DFG motif. Several compounds inhibited cellular RSK2 activity, and we identified compounds that uncoupled cellular RSK2 inhibition from potent cytotoxicity in the MOLM-13 AML cell line. These N-substituted probes have revealed an opportunity to further examine substituents that extend from the ATP- to the substrate-binding site may confer improved RSK potency and selectivity.

N-heterocyclic derivatives as NOS inhibitors

N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

Substituted hydroxylaminopurines and related derivatives. Synthesis and screening tests.

-